Drajon Health, Toodyay, Australia.
IMVS - Clinical Biochemistry, Adelaide, South Australia.
Ann Clin Biochem. 2021 May;58(3):196-202. doi: 10.1177/0004563220987589. Epub 2021 Jan 14.
Changes were made to the Australian guidelines for vitamin D testing in November 2014 which restricted the patients who could be tested and reimbursed under the Medical Benefits Schedule. A retrospective study was conducted to assess the impact of the changes.
Data from 588,021 cases tested for vitamin D over the period of 2014 to 2017 were obtained and the results in 149,808 cases tested before the change in guidelines were compared to 438,213 cases tested afterwards.
The results showed an initial fall in requests took place after the introduction of changes, but request numbers had returned to pre-change levels by November 2016. Furthermore, following the intervention, there was a significant reduction in the number of cases of vitamin D deficiency (<50 nmol/L) detected after November 2014 ( < 0.001) with odds ratio (OR) calculations showing the strongest effect for the sub-cohort of 0-20 nmol/L (OR = 1.77). For patient vitamin D levels >71 nmol/L, the pattern of detection inverted with more cases of sufficiency being detected after the intervention than before (OR from 0.84 to 0.48, <0.001).
The failure to show a sustained reduction in vitamin D testing is a common finding with demand management strategies to limit test requesting. More significant is the failure of the intervention to improve the detection of vitamin D deficiency. These failures highlight the need for better tools to manage test requesting including the use of audit and outcomes measurement to guide future interventions.
2014 年 11 月,澳大利亚对维生素 D 检测指南进行了修订,限制了可以根据《医疗福利计划》进行检测和报销的患者。本研究旨在评估这些变化的影响。
收集了 2014 年至 2017 年期间 588021 例维生素 D 检测数据,将指南修订前的 149808 例检测结果与修订后的 438213 例检测结果进行比较。
结果显示,在指南修订后,检测请求数量最初有所下降,但到 2016 年 11 月已恢复到修订前的水平。此外,干预后,2014 年 11 月后检测到的维生素 D 缺乏症(<50nmol/L)的病例数显著减少(<0.001),OR 计算显示,0-20nmol/L 亚组的影响最强(OR=1.77)。对于维生素 D 水平>71nmol/L 的患者,检测结果出现反转,干预后检测到的充足病例数多于干预前(OR 从 0.84 降至 0.48,<0.001)。
限制检测请求的需求管理策略未能持续减少维生素 D 检测,这一结果较为常见。更重要的是,干预措施未能提高维生素 D 缺乏症的检出率。这些失败突显了需要更好的工具来管理检测请求,包括使用审核和结果测量来指导未来的干预措施。